Madrigal Pharmaceuticals (MDGL) Research & Development (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Research & Development data on file, last reported at $108.7 million in Q1 2026.

• On a quarterly basis, Research & Development rose 146.07% year-over-year to $108.7 million in Q1 2026; TTM through Mar 2026 was $453.0 million, a 105.09% increase from a year earlier, with the FY2025 full-year figure at $388.5 million, up 64.13% from the prior year.
• Research & Development for Q1 2026 stood at $108.7 million, down from $116.3 million in the prior quarter.
• Over the last five years, Research & Development for MDGL reached as high as $174.0 million in Q3 2025 and fell as low as $36.9 million in Q4 2024.
• Historically, Research & Development has averaged $74.3 million across 5 years, with a median of $68.7 million in 2024.
• Across the five-year window, Research & Development slumped 47.76% in 2024 and surged 215.09% in 2025, its largest moves.
• Year by year, Research & Development stood at $70.7 million in 2022, then retreated by 0.14% to $70.6 million in 2023, then slumped by 47.76% to $36.9 million in 2024, then jumped by 215.09% to $116.3 million in 2025, then fell by 6.52% to $108.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $108.7 million in Q1 2026, $116.3 million in Q4 2025, and $174.0 million in Q3 2025.